Kiora Pharmaceuticals Inc. Watch

from 8-K 39 pages 1,447,628 Shares of Common Stock, 3,908 Shares of Series F Convertible Preferred Stock (Convertible Into 3,552,372 Shares of Common Stock) and 5,000,000 Class C Warrants (Exercisable for 5,000,000 Shares of Common Stock) 5,000,000 Class D Warrants (Exercisable for 5,000,000 Shares of Common Stock) of Kiora Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 39 pages Shares of Common Stock, Shares of Series F Convertible Preferred Stock (Convertible Into Shares of Common Stock) and Class C Warrants (Exercisable for Shares of Common Stock) Class D Warrants (Exercisable for Shares of Common Stock) of Kiora Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 44 pages Shares of Common Stock, Shares of Series F Convertible Preferred Stock (Convertible Into Shares of Common Stock) and Warrants (Exercisable for Shares of Common Stock) of Kiora Pharmaceuticals, Inc. Underwriting Agreement

from 8-K 43 pages 19,770,172 Shares of Common Stock, 1,280 Shares of Series E Convertible Preferred Stock (Convertible Into 6,400,000 Shares of Common Stock) 26,170,172 Class a Warrants (Exercisable for 26,170,172 Shares of Common Stock) and 26,170,172 Class B Warrants (Exercisable for 26,170,172 Shares of Common Stock) of Kiora Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 43 pages Shares of Common Stock, Shares of Series E Convertible Preferred Stock (Convertible Into Shares of Common Stock) Class a Warrants (Exercisable for Shares of Common Stock) and Class B Warrants (Exercisable for Shares of Common Stock) of Kiora Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 43 pages Shares of Common Stock, Shares of Series E Convertible Preferred Stock (Convertible Into Shares of Common Stock) and Warrants (Exercisable for Shares of Common Stock) of Kiora Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 43 pages Shares of Common Stock, Shares of Series E Convertible Preferred Stock (Convertible Into Shares of Common Stock) and Warrants (Exercisable for Shares of Common Stock) of Kiora Pharmaceuticals, Inc. Underwriting Agreement

from SC 13D/A 1 page This Undersigned Hereby Agree, Pursuant to Rule 13d-1(k)(1) Under the Securities Exchange Act of 1934, as Amended (The “Act”), That a Statement of Beneficial Ownership as Required Under Sections 13(g) or 13(d) of the Act and the Rules Promulgated Thereunder May Be Filed on Each of Their Behalf on Schedule 13g or Schedule 13d, as Appropriate, and That Said Joint Filing May Thereafter Be Amended by Further Joint Filings

from SC 13D/A 2 pages This Undersigned Hereby Agree, Pursuant to Rule 13d-1(k)(1) Under the Securities Exchange Act of 1934, as Amended (The “Act”), That a Statement of Beneficial Ownership as Required Under Sections 13(g) or 13(d) of the Act and the Rules Promulgated Thereunder May Be Filed on Each of Their Behalf on Schedule 13g or Schedule 13d, as Appropriate, and That Said Joint Filing May Thereafter Be Amended by Further Joint Filings. Fcpi Innoven Europe By: Ipsa (Formerly Innoven Partenaires S.A.), Manager Fcpi Innoven Europe 2 By: Ipsa (Formerly Innoven Partenaires S.A.), Manager Fcpi Innoven Capital 2 By: Ipsa (Formerly Innoven Partenaires S.A.), Manager Fcpi Poste Innovation By: Ipsa (Formerly Innoven Partenaires S.A.), Manager Fcpi Poste Innovation 2 By: Ipsa (Formerly Innoven Partenaires S.A.), Manager Fcpi Poste Innovation 3 By: Ipsa (Formerly Innoven Partenaires S.A.), Manager Fcpi Poste Innovation 5 By: Ipsa (Formerly Innoven Partenaires S.A.), Manager Fcpi Poste Innovation 6 By: Ipsa (Formerly Innoven Partenaires S.A.), Manager Fcpi La Banque Postale Innovation 1 By: Ipsa (Formerly Innoven Partenaires S.A.), Manager

from SC 13D/A 2 pages This Undersigned Hereby Agree, Pursuant to Rule 13d-1(k)(1) Under the Securities Exchange Act of 1934, as Amended (The “Act”), That a Statement of Beneficial Ownership as Required Under Sections 13(g) or 13(d) of the Act and the Rules Promulgated Thereunder May Be Filed on Each of Their Behalf on Schedule 13g or Schedule 13d, as Appropriate, and That Said Joint Filing May Thereafter Be Amended by Further Joint Filings

from 8-K 44 pages Underwriting Agreement Between Eyegate Pharmaceuticals, Inc. and Aegis Capital Corp., as Representative of the Several Underwriters Eyegate Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 44 pages Underwriting Agreement Between Eyegate Pharmaceuticals, Inc. and Aegis Capital Corp., as Representative of the Several Underwriters Eyegate Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 44 pages Underwriting Agreement Between Eyegate Pharmaceuticals, Inc. and Aegis Capital Corp., as Representative of the Several Underwriters Eyegate Pharmaceuticals, Inc. Underwriting Agreement

from SC 13D 1 page This Undersigned Hereby Agree, Pursuant to Rule 13d-1(k)(1) Under the Securites Exchange Act of 1934, as Amended (The “Act”), That a Statement of Beneficial Ownership as Required Under Sections 13(g) or 13(d) of the Act and the Rules Promulgated Thereunder May Be Filed on Each of Their Behalf on Schedule 13g or Schedule 13d, as Appropriate, and That Said Joint Filing May Thereafter Be Amended by Further Joint Filings

from SC 13D 2 pages This Undersigned Hereby Agree, Pursuant to Rule 13d-1(k)(1) Under the Securites Exchange Act of 1934, as Amended (The “Act”), That a Statement of Beneficial Ownership as Required Under Sections 13(g) or 13(d) of the Act and the Rules Promulgated Thereunder May Be Filed on Each of Their Behalf on Schedule 13g or Schedule 13d, as Appropriate, and That Said Joint Filing May Thereafter Be Amended by Further Joint Filings

from S-1/A 61 pages Underwriting Agreement Between Eyegate Pharmaceuticals, Inc. and Aegis Capital Corp., as Representative of the Several Underwriters Eyegate Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 60 pages Underwriting Agreement Between Eyegate Pharmaceuticals, Inc. and Aegis Capital Corp., as Representative of the Several Underwriters Eyegate Pharmaceuticals, Inc. Underwriting Agreement

from S-1/A 59 pages Underwriting Agreement Between Eyegate Pharmaceuticals, Inc. and Aegis Capital Corp., as Representative of the Several Underwriters Eyegate Pharmaceuticals, Inc. Underwriting Agreement